Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Go back to Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 1.97 -0.06 (2.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.03 | 52 Week High | $19.41 | |||
| Open | $2.03 | 52 Week Low | $4.83 | |||
| Day High | $2.09 | P/E | N/A | |||
| Day Low | $1.92 | EPS | $-2.74 | |||
| Volume | 1,108,945 | |||||
